Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Neoadjuvant Chemotherapy for Resectable Esophageal Carcinoma: A Meta-analysis of Randomized Clinical Trials

  • Xu, Xiao-Hua (Department of Preventive Medicine, Shantou University Medical College) ;
  • Peng, Xue-Hong (the First Affiliated Hospital of Shantou University Medical College) ;
  • Yu, Ping (Department of Computer, Shantou University Medical College) ;
  • Xu, Xiao-Yuan (Department of Cell Biology, Shantou University Medical College) ;
  • Cai, Er-Hui (Department of Preventive Medicine, Shantou University Medical College) ;
  • Guo, Pi (Department of Preventive Medicine, Shantou University Medical College) ;
  • Li, Ke (Department of Preventive Medicine, Shantou University Medical College)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Neoadjuvant chemotherapy for resectable esophageal carcinoma has been a focus of study, but no agreement has been reached on clinical randomized controlled trials and relevant systematic evaluation. The purpose of this study was to perform a meta-analysis on published randomized controlled trials (RCTs) that compared neoadjuvant chemotherapy and surgery with surgery alone for resectable esophageal carcinoma. Medline and manual searches was conducted in PubMed, ASCO (American Society of Clinical Oncology) meeting summary, Embase, the Cochrane Library (up to October 2010), Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Database, Wanfang Database. The selection contents were to identify all published and unpublished RCTs that compared neoadjuvant chemotherapy and surgery with surgery alone for resectable esophageal carcinoma. Sixteen RCTs which included 2,594 patients were selected. The risk ratio (RR) (95% confidence interval [CI]; P value), expressed as neoadjuvant chemotherapy and surgery versus surgery alone (treatment versus control), was 1.02 (0.95, 1.10; P=0.54) for 1-year survival, 1.29 (1.13, 1.47; P=0.0001) for 3-year survival, 1.31 (1.13, 1.51; P=0.0003) for 5-year survival, 1.00 (0.95, 1.04; P= 0.85) for rate of resection and 0.89 (0.64, 1.23; P=0.48) for operative mortality. The results showed that neoadjuvant chemotherapy for resectable esophageal carcinoma can raise the overall survival rate of patients with esophageal carcinoma, but it does not affect treatment-related mortality.

Keywords

References

  1. AAllum WH, Stenning SP, Bancewicz J, et al (2009). Longterm results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27, 5062-7. https://doi.org/10.1200/JCO.2009.22.2083
  2. Ancona E, Ruol A, Santi S, et al (2001). Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer, 91, 2165-74. https://doi.org/10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H
  3. Ando N, Ozawa S, Kitagawa Y, et al (2000). Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg, 232, 225-32. https://doi.org/10.1097/00000658-200008000-00013
  4. Baba M, Natsugoe S, Shimada M, et al (2000). Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus, 13, 136-41. https://doi.org/10.1046/j.1442-2050.2000.00101.x
  5. Bokhyan V, Stilidi I, Malikhova O, et al (2009). Neoadjuvant chemotherapy followed by transthoracic resection for locally advanced carcinoma of the esophagus: a randomized study. European Journal of Cancer Supplements, 7, 377.
  6. Bollschweiler E, Wolfgarten E, Gutschow C, et al (2001). Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer, 92, 549-55. https://doi.org/10.1002/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0.CO;2-L
  7. Cao XF, Wu BC, Wang S, et al (2001). A study of esophageal cancer systemic therapy mode with surgery as the main treatment. Chinese J Clinic Oncol Rehabilitation, 8, 25-6.
  8. Crew KD, Neugut AI, (2004). Epidemiology of upper gastrointestinal malignancies. Semin Oncol, 31, 450-64. https://doi.org/10.1053/j.seminoncol.2004.04.021
  9. Cunningham D, Allum WH, Stenning SP, et al (2001). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.
  10. Eslick GD (2009). Epidemiology of esophageal cancer. Gastroenterol Clin North Am, 38, 17-25 https://doi.org/10.1016/j.gtc.2009.01.008
  11. Gebski V, Burmeister B, Smithers BM, et al (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 8, 226-34. https://doi.org/10.1016/S1470-2045(07)70039-6
  12. Greil R, Stein HJ (2007). Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol, 8, 189-90. https://doi.org/10.1016/S1470-2045(07)70053-0
  13. Higgins JPT, Green S, editors (2009). Assessing risk of bias in included studies: Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009], The Cochrane Collaboration, Available from www.cochranehandbook. org.
  14. Igaki H, Koto H, Ando N, et al (2008). A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/IIIsquamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol, 26, S4510. https://doi.org/10.1200/jco.2008.26.15_suppl.4510
  15. Iyer R, Wilkinson N, Demmy T, et al (2004). Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined- modality therapy. Ann Surg Oncol, 11, 665-73. https://doi.org/10.1245/ASO.2004.10.026
  16. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  17. Kaklamanos IG, Walker GR, Ferry K, et al (2003). Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol, 10, 754-61. https://doi.org/10.1245/ASO.2003.03.078
  18. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50. https://doi.org/10.1200/JCO.2005.05.2308
  19. Katlic MR, Wilkins EJ, Grillo HC (1997). Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg, 99, 929-38.
  20. Kelsen D (1997). Multimodality therapy for adenocarcinoma of the esophagus. Gastroenterol Clin North Am, 26, 635-45. https://doi.org/10.1016/S0889-8553(05)70319-8
  21. Kelsen DP, Ginsberg R, Pajak TF, et al (1998). Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 339, 1979-84. https://doi.org/10.1056/NEJM199812313392704
  22. Kelsen DP, Winter KA, Gunderson LL, et al (2007). Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol, 25, 3719-25. https://doi.org/10.1200/JCO.2006.10.4760
  23. Khushalani N (2008). Cancer of the esophagus and stomach. Mayo Clin Proc, 83, 712-22. https://doi.org/10.1016/S0025-6196(11)60900-2
  24. Law S, Fok M, Chow S, et al (1997). Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg, 114, 210-7. https://doi.org/10.1016/S0022-5223(97)70147-8
  25. Liao QM, Wang XY, Yi NT, et al (1993). Preoperative chemotherapy for esophageal carcinoma in contrast with single surgery on local lymph nodes metastasis and curative effect. Henan J Oncol 6, 34-6.
  26. Ma BQ, Zhang YF, Guo HZ (2007). Neoadjuvant chemotherapy for stage III esophageal squamous cell carcinoma. China J Modern Med, 17, 2244-6.
  27. Maipang T, Vasinanukorn P, Petpichetchian C, et al (1994). Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol, 56, 191-7. https://doi.org/10.1002/jso.2930560314
  28. Malthaner R, Fenlon D (2003). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev, 4, CD001556.
  29. Medical Research Council Oesophageal Cancer Working Group (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 359, 1727-33. https://doi.org/10.1016/S0140-6736(02)08651-8
  30. Meyenberger C, Fantin AC (2000). Esophageal carcinoma: current staging strategies. Recent Results Cancer Res, 155, 63-72. https://doi.org/10.1007/978-3-642-59600-1_6
  31. Millar J, Scullin P, Morrison A, et al (2005). Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer, 93, 1112-6. https://doi.org/10.1038/sj.bjc.6602842
  32. Nygaard K, Hagen S, Hansen HS, et al (1992). Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg, 16, 1104-10. https://doi.org/10.1007/BF02067069
  33. Orringer MB, Marshall B, Iannettoni MD (1999). Transhiatal esophagectomy: clinical experience and refinements. Ann Surg, 230, 392-403. https://doi.org/10.1097/00000658-199909000-00012
  34. Parkin DM, Muir CS, (1992). Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ, 1992, 45-173.
  35. Peng Y, Du YB, Ma YF (2007). Clinical analysis of preoperative new adjuvant chemotherapy in local advanced esophageal carcinoma. Chinese J Practice Med, 6, 780-1.
  36. Peng Y, Du YB, Ma YF (2007). Clinical analysis of preoperative new adjuvant chemotherapy in local advanced esophageal carcinoma. Chinese J Practice Med, 6, 780-1.
  37. Roth JA, Pass HI, Flanagan MM, et al (1998). Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg, 96, 242-8.
  38. Schlag PM (1992). Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg, 127, 1446-50. https://doi.org/10.1001/archsurg.1992.01420120080015
  39. Shah MA, Kelsen DP (2004). Combined modality therapy of esophageal cancer: changes in the standard of care? Ann Surg Oncol, 11, 641-3. https://doi.org/10.1245/ASO.2004.04.907
  40. Sutton P, Clark P (2000). Neo-adjuvant treatment for oesophageal cancer. GI Cancer, 3, 231-8.
  41. Urschel JD, Vasan H, Blewett CJ (2002). A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg, 183, 274-9. https://doi.org/10.1016/S0002-9610(02)00795-X
  42. van Meerten E, Eskens FA, van Gameren EC, et al (2007). Firstline treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer, 96, 1348-52. https://doi.org/10.1038/sj.bjc.6603750
  43. Wang CL, Ding T, Chang LB, et al (2001). A randomized clinical study of preoperative chemotherapy for esophageal carcinoma. Chin J Oncol, 23, 254-5.
  44. Whooley BP, Law S, Murthy SC, et al (2001). Analysis of reduced death and complication rates after esophageal resection. Ann Surg, 233, 338-44. https://doi.org/10.1097/00000658-200103000-00006
  45. Zhu K, Li K, Dang CX, et al (2008). Effect of neo-adjuvant chemotherapy (BPF regimen) on the expression of MVD and VEGF in esophageal carcinoma. China Cancer, 17, 518-20.

Cited by

  1. Integrin alpha 6: A novel therapeutic target in esophageal squamous cell carcinoma vol.43, pp.5, 2013, https://doi.org/10.3892/ijo.2013.2097
  2. CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome vol.62, pp.7, 2013, https://doi.org/10.1111/his.12111
  3. Prognostic Significance of Beta-Catenin Expression in Patients with Esophageal Carcinoma: a Meta-analysis vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6103
  4. Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma vol.36, pp.10, 2015, https://doi.org/10.1007/s13277-015-3443-x
  5. Current status of proteomics of esophageal carcinoma vol.13, pp.11, 2016, https://doi.org/10.1080/14789450.2016.1242418